Esperion appoints Seth H.Z. Fischer to its Board of Directors, effective Oct 28, 2021

Esperion Therapeutics, Inc.

Seth H.Z. Fischer elected as Class III director for term expiring at 2022 annual meeting.
Fischer brings 35+ years pharma/device experience; former CEO of Vivus, group chairman at Johnson & Johnson.
Will serve as chair of Nominating and Governance Committee and member of Compliance Committee.
Board determined Fischer is an independent director under SEC and Nasdaq rules.
Fischer receives standard non-employee director compensation; indemnification agreement executed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Seth H.Z. Fischer

Director

ESPR · Esperion Therapeutics, Inc.

Effective: 2021-10-28
Filed: November 1, 2021, 7:59 PM ET

On October 28, 2021, the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) elected Seth H.Z. Fischer to fill in the newly created vacancy on the Board resulting from an increase in size of the Board from eight (8) directors to nine (9) directors, effective October 28, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Seth H.Z. Fischer was elected as Director at Esperion Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On October 28, 2021, the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) elected Seth H.Z. Fischer to fill in the newly created vacancy on the Board resulting from an increase in size of the Board from eight (8) directors to nine (9) directors, effective October 28, 2021.

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-132367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.